Seroprevalence in Argentinian healthcare workers after vaccination with Sputnik V
Background: Healthcare workers (HCW) were deeply affected by coronavirus disease 2019 (COVID-19). Therefore, vaccination of this population is crucial. However, data on Sputnik V vaccine are sparse.
Objective: The aim of this study was to evaluate serological responses in HCWs following two doses of Sputnik V vaccine.
Methods: A cross-sectional study was conducted at a tertiary-care private teaching hospital between April and May 2021. HCWs without a history of COVID-19 3 or more weeks after the second dose of Sputnik V had a fresh serum sample extracted and processed using Abbott® SARS-CoV-2 IgG II Quant. Values equal to or over 50 arbitrary units (AU)/mL were considered positive. Primary outcome was the proportion of participants who developed antibodies 21 or more days after the second dose of Sputnik V. Secondary outcomes were concentration of anti-spike IgG antibodies and comparison of such concentrations between samples taken 3–5 weeks and more than 5 weeks after the second dose.
Results: The entire population developed anti-spike IgG antibodies. The median antibody concentration was 1234.8 AU/mL. When analysing days to extraction from second vaccine dose, there was no statistical difference between 21 and 35 days versus more than 35 days.
Conclusion: Vaccination with Sputnik V in HCW at our institution demonstrated an efficacy of 100% in achieving quantifiable anti-spike IgG antibodies 21 or more days after the second dose.
COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available from: https://coronavirus.jhu.edu/map.html [cited 7 June 2021].
Organización Panamericana de la Salud / Organización Mundial de la Salud. Actualización epidemiológica: Enfermedad por Coronavirus (COVID-19). 2 de diciembre de 2021, Washington, D.C.: OPS/OMS; 2021. Accessed December 26, 2021. Available at https://www.paho.org/es/documentos/actualizacion-epidemiologica-enfermedad-por-coronavirus-covid-19-2-diciembre-202.
Hughes MM, Groenewold MR, Lessem SE, Xu K, Ussery EN, Wiegand RE, et al. Update: characteristics of health care personnel with COVID-19 – United States, February 12–July 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 1364–8. doi: 10.15585/mmwr.mm6938a3
Logunov D, Dolzhikova I, Shcheblyakov D, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021; 397: 671–81. doi: 10.1016/S0140-6736(21)00234-8
Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 [published online ahead of print, 2021 Apr 21]. N Engl J Med 2021; 384: 2187–201. doi: 10.1056/NEJMoa2101544
Baden LR, El Sahly H, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384: 403–16. doi: 10.1056/NEJMoa2035389
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–15. doi: 10.1056/NEJMoa2034577
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK [published correction appears in Lancet 2021 Jan 9; 397: 98]. Lancet 2021; 397: 99–111. doi: 10.1016/S0140-6736(20)32661-1
Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Ogutuyo KY, et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Version 3. medRxiv. Preprint. NaN NaN [revised 2021 May 29]. doi: 10.1101/2021.03.31.21254660
Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. 2021. Accessed December 26, 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html.
Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, Kaiser L, et al. Definitions for COVID-19 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect 2021; 27: 315–8. doi: 10.1016/j.cmi.2020.11.028
Birhane M, Bressler S, Chang G, Clark T, Dorough L, Fischer M, et al. COVID-19 vaccine breakthrough infections reported to CDC – United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 792–3. doi: 10.15585/mmwr.mm7021e3
Empleo de la vacuna Sputnik V en Argentina: Evaluación de respuesta humoral frente a la vacunación Informe parcial Enero-Marzo 2021. Accessed December 26, 2021. Available from: https://www.argentina.gob.ar/sites/default/files/informe_sputnik_buenos_aires_3.03.2021v1.pdf.
Copyright (c) 2022 Daniela Santonato, María A. Malvicini, Andrea Novau, Silvio F. Torres, Alejandro Siaba Serrate, María V. Romano, Pablo G. Brenzoni, Leonardo Fabbro, Laura Paulosky, Wanda Cornistein
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to IJIC. Read the full Copyright- and Licensing Statement.